



Supplementary Figure 1: Impact of introducing whole-genome sequencing and/or molecular testing on numbers of patients starting treatment each year for (a) active-TB patients (drug-sensitive and multidrug-resistant), and (b) latent TB infection (LTBI). Strategies we consider are standard drug sensitivity testing (DST) being replaced by whole-genome sequencing (WGS: red bars), or molecular testing (X or U) being introduced into the conventional TB-diagnosis pathway with DST (X + DST: blue bars, U + DST: green bars), or molecular testing being introduced into the conventional pathway with WGS in place of DST (X + WGS: purple bars, U + WGS: orange bars). The boxes show the interquartile ranges, and the whiskers the 95% ranges, of the calculated values. TB: tuberculosis.